On April 16, 2026, Roche announced it will initiate a new, global, pivotal Phase III study for Elevidys™ (delandistrogene moxeparvovec), the first approved gene therapy to treat the underlying cause of Duchenne muscular dystrophy (DMD), with the intent to expand patient access.
To read their full release, please visit https://assets.roche.com/f/176343/x/30cd5dd5da/elevidys-media-statement_april-2026.pdf.
